Processa (NASDAQ: PCSA) officer adds to stake with share purchase

Rhea-AI Filing Summary

Processa Pharmaceuticals Chief Business-Strategy Officer Patrick Lin bought additional company stock. On an open-market purchase, he acquired 1,582 shares of common stock at $2.57 per share. After this trade, he directly owns 9,176 shares. A separate holding entry shows 1,740 shares held indirectly through the Lin Family Trust dated February 4, 2024.

Insider Trade Summary

Net Buyer: 1,582 shares ($4,066)

Net Buy 2 txns

Insider Lin Patrick

Role Chief Business - Strategy Off

Bought 1,582 shs ($4K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,582	$2.57	$4K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 9,176 shares (Direct, null); Common Stock — 1,740 shares (Indirect, Lin Family Trust Feb 4, 2024)

Footnotes (1)

Key Figures

Shares purchased: 1,582 shares Purchase price: $2.57 per share Direct holdings after transaction: 9,176 shares +2 more

5 metrics

Shares purchased 1,582 shares Open-market purchase of common stock

Purchase price $2.57 per share Price paid for 1,582 common shares

Direct holdings after transaction 9,176 shares Common stock held directly by Patrick Lin

Indirect holdings after transaction 1,740 shares Common stock held via Lin Family Trust Feb 4, 2024

Net buy direction 1,582 net-buy shares transactionSummary netBuySellShares

Key Terms

open-market purchase, indirect ownership, Lin Family Trust Feb 4, 2024

3 terms

open-market purchase financial

"The transaction was an open-market purchase at $2.57 per share"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

indirect ownership financial

"1,740 shares held indirectly through the Lin Family Trust"

Lin Family Trust Feb 4, 2024 financial

"shares held indirectly through the Lin Family Trust dated February 4, 2024"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lin Patrick

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FLORIDA 32960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business - Strategy Off

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/29/2026		P		1,582	A	$2.57	9,176	D
Common Stock								1,740	I	Lin Family Trust Feb 4, 2024

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Patrick Lin by John J. Wolfel, as Attorney-in-Fact	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Patrick Lin report for PCSA?

Patrick Lin reported buying 1,582 shares of Processa Pharmaceuticals common stock. The transaction was an open-market purchase at $2.57 per share, increasing his directly held position and signaling additional personal exposure to the company’s equity.

At what price did Patrick Lin buy Processa Pharmaceuticals (PCSA) shares?

Patrick Lin purchased 1,582 Processa Pharmaceuticals shares at $2.57 per share. This was classified as an open-market purchase, indicating he bought the stock on the market rather than receiving shares through compensation or option exercises.

How many Processa Pharmaceuticals (PCSA) shares does Patrick Lin now hold directly?

Following the reported transaction, Patrick Lin directly holds 9,176 shares of Processa Pharmaceuticals common stock. This figure reflects his position after buying 1,582 shares in the open market at $2.57 per share on the reported transaction date.

Does Patrick Lin have any indirect holdings of PCSA shares?

Yes. The Form 4 shows 1,740 Processa Pharmaceuticals shares held indirectly through the Lin Family Trust dated February 4, 2024. These trust-held shares are reported as indirect ownership, separate from his 9,176 directly owned shares.

What type of transaction code was used in Patrick Lin’s PCSA filing?

The transaction used code P, which denotes an open-market or private purchase of common stock. This code confirms that Patrick Lin’s acquisition of 1,582 Processa Pharmaceuticals shares was a buy transaction rather than an option exercise or other non-market event.